

Resource Summary Report

Generated by T1D on Sep 19, 2026

STAR

RRID:SCR_004463

Type: Tool

Proper Citation

STAR (RRID:SCR_004463)

Resource Information

URL: <http://code.google.com/p/rna-star/>

Proper Citation: STAR (RRID:SCR_004463)

Description: Software performing alignment of high-throughput RNA-seq data. Aligns RNA-seq reads to reference genome using uncompressed suffix arrays.

Synonyms: Spliced Transcripts Alignment to Reference, Spliced Transcripts Alignment to a Reference (STAR), rna-star, ultrafast universal RNA-seq aligner

Resource Type: alignment software, data processing software, image analysis software, software application, software resource

Defining Citation: [PMID:23104886](https://pubmed.ncbi.nlm.nih.gov/23104886/), [DOI:10.1093/bioinformatics/bts635](https://doi.org/10.1093/bioinformatics/bts635)

Keywords: RNA-seq data, alignment, RNA-seq reads alignment, reference genome, using uncompressed suffix arrays, bio.tools

Funding: NHGRI U54 HG004557

Resource Name: STAR

Resource ID: SCR_004463

Alternate IDs: biotools:star, OMICS_01254, SCR_015899

Alternate URLs: <https://github.com/alexdobin/STAR>, <https://bio.tools/star>, <https://sources.debian.org/src/rna-star/>

License: GNU General Public License, v3

Record Creation Time: 20220129T080224+0000

Record Last Update: 20260919T195038+0000

Ratings and Alerts

No rating or validation information has been found for STAR.

No alerts have been found for STAR.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 26381 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Tao Y, et al. (2026) TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. Cancer research, 86(9), 2161.

Gauthier J, et al. (2026) B cell-intrinsic IL-2 signaling regulates inflammation by promoting IL-10 expression in CD25+ age-associated B cells. Immunity, 59(2), 354.

Aulakh S, et al. (2026) Fusion transcriptome landscape in glioblastoma: Incidence and therapeutic implications. Neuro-oncology advances, 8(1), vda238.

Ishihara H, et al. (2026) Non-Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors. Molecular cancer research : MCR, 24(5), 390.

Adams NM, et al. (2026) Chromatin-mediated anticipatory control of type I interferon production in plasmacytoid dendritic cells. Immunity, 59(2), 270.

Hofvander J, et al. (2026) Transcriptomic Subgroups in Soft Tissue Tumors Correlate with Morphologic Subtype, Genomic Features, and Outcome. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(9), 1825.

Swancutt KL, et al. (2026) Immune Stromal Components Impede Biological Effectiveness of Carbon Ion Therapy in a Preclinical Model of Pancreatic Ductal Adenocarcinoma. Molecular cancer therapeutics, 25(2), 333.

Sekiguchi N, et al. (2026)

Circ72309 modulates gemcitabine metabolism and gemcitabine sensitivity in pancreatic cancer: Serum Circ72309 levels as a potential predictor of treatment response

. International journal of oncology, 68(3).

Muppirala AN, et al. (2026) Tachykinin signaling defines distinct populations of glia in the enteric nervous system. Neuron.

Liu L, et al. (2026) PRMT5 upregulates KCNMB4 expression via histone methylation to promote paclitaxel resistance in advanced nasopharyngeal carcinoma. Cell death &

disease, 17(1), 19.

Yan C, et al. (2026) RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b+ Bregs thereby overcoming melanoma PD1-resistance. *Nature communications*, 17(1), 162.

Yuan DJ, et al. (2026) Genotype-to-Phenotype Mapping of Somatic Clonal Mosaicism via Single-Cell Co-Capture of DNA Mutations and mRNA Transcripts. *Cancer discovery*, 16(4), 721.

Boudjadi S, et al. (2026) Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma. *Molecular cancer therapeutics*, 25(3), 493.

Zeng TB, et al. (2026) SETDB1 enables development beyond cleavage stages by extinguishing the MERVL-driven two-cell totipotency transcriptional program in the mouse embryo. *eLife*, 15.

Tran B, et al. (2026) Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(14), 2850.

Lyu P, et al. (2026) Genetic variation reveals a homeotic long noncoding RNA that modulates human hematopoietic stem cells. *Cell*, 189(13), 4022.

Guillon M, et al. (2026) MECP2 mutations rewire human ESC fate and bias cortical lineage commitment. *Stem cell reports*, 21(5), 102895.

Purohit TA, et al. (2026) Genetic loss of CHD1 regulates distinct histone post-translational modifications in the development of castration-resistant prostate cancer. *Neoplasia (New York, N.Y.)*, 73, 101289.

Ferreira S, et al. (2026) Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment. *Cancer research*, 86(13), 3109.

Wu X, et al. (2026) Locus-Specific Human Endogenous Retrovirus ERVK18 Expression Indicates an Inflamed Microenvironment and Favorable Immunotherapy Outcome in Small Cell Lung Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(11), 2214.